Literature DB >> 20508613

Graft-versus-host driven graft-versus-leukemia effect of minor histocompatibility antigen HA-1 in chronic myeloid leukemia patients.

T Mutis, R Brand, D Gallardo, A van Biezen, D Niederwieser, E Goulmy.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20508613     DOI： 10.1038/leu.2010.115

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  13 in total

Review 1.  Personal tumor antigens in blood malignancies: genomics-directed identification and targeting.

Authors:  Livius Penter; Catherine J Wu
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

2.  Current status of immunotherapy for the treatment of lung cancer.

Authors:  Sanjay Murala; Vamsi Alli; Daniel Kreisel; Andrew E Gelman; Alexander S Krupnick
Journal:  J Thorac Dis       Date:  2010-12       Impact factor: 2.895

3.  Association of disparities in known minor histocompatibility antigens with relapse-free survival and graft-versus-host disease after allogeneic stem cell transplantation.

Authors:  Willemijn Hobo; Kelly Broen; Walter J F M van der Velden; Annelies Greupink-Draaisma; Niken Adisty; Yannick Wouters; Michel Kester; Hanny Fredrix; Joop H Jansen; Bert van der Reijden; J H Frederik Falkenburg; Theo de Witte; Frank Preijers; Ton Schattenberg; Ton Feuth; Nicole M Blijlevens; Nicolaas Schaap; Harry Dolstra
Journal:  Biol Blood Marrow Transplant       Date:  2012-09-27       Impact factor: 5.742

4.  Efficacy of host-dendritic cell vaccinations with or without minor histocompatibility antigen loading, combined with donor lymphocyte infusion in multiple myeloma patients.

Authors:  R Oostvogels; E Kneppers; M C Minnema; R C Doorn; L E Franssen; T Aarts; M E Emmelot; E Spierings; I Slaper-Cortenbach; K Westinga; E Goulmy; H M Lokhorst; T Mutis
Journal:  Bone Marrow Transplant       Date:  2016-11-14       Impact factor: 5.483

5.  Proteogenomic-based discovery of minor histocompatibility antigens with suitable features for immunotherapy of hematologic cancers.

Authors:  D P Granados; A Rodenbrock; J-P Laverdure; C Côté; O Caron-Lizotte; C Carli; H Pearson; V Janelle; C Durette; E Bonneil; D C Roy; J-S Delisle; S Lemieux; P Thibault; C Perreault
Journal:  Leukemia       Date:  2016-02-09       Impact factor: 11.528

6.  Stem Cell Transplantation for Hematological Malignancies: Prospects for Personalized Medicine and Co-therapy with Mesenchymal Stem Cells.

Authors:  Shyam A Patel; Pranela Rameshwar
Journal:  Curr Pharmacogenomics Person Med       Date:  2011-09-01

Review 7.  Cell therapies for hematological malignancies: don't forget non-gene-modified t cells!

Authors:  Melanie L Grant; Catherine M Bollard
Journal:  Blood Rev       Date:  2017-11-27       Impact factor: 8.250

Review 8.  Minor histocompatibility Ags: identification strategies, clinical results and translational perspectives.

Authors:  R Oostvogels; H M Lokhorst; T Mutis
Journal:  Bone Marrow Transplant       Date:  2015-10-26       Impact factor: 5.483

Review 9.  Effect of MHC and non-MHC donor/recipient genetic disparity on the outcome of allogeneic HCT.

Authors:  Edus H Warren; Xinyi Cindy Zhang; Shuying Li; Wenhong Fan; Barry E Storer; Jason W Chien; Michael J Boeckh; Lue Ping Zhao; Paul J Martin; John A Hansen
Journal:  Blood       Date:  2012-08-02       Impact factor: 22.113

10.  Towards effective and safe immunotherapy after allogeneic stem cell transplantation: identification of hematopoietic-specific minor histocompatibility antigen UTA2-1.

Authors:  R Oostvogels; M C Minnema; M van Elk; R M Spaapen; G D te Raa; B Giovannone; A Buijs; D van Baarle; A P Kater; M Griffioen; E Spierings; H M Lokhorst; T Mutis
Journal:  Leukemia       Date:  2012-10-01       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.